Indivior Pharmaceuticals (INDV) Revenue (2024 - 2026)

Indivior Pharmaceuticals' Revenue history runs 3 years deep, the most recent figure standing at $317.0 million for Q1 2026.

• On a quarterly basis, Revenue rose 19.17% year-over-year to $317.0 million in Q1 2026; TTM through Mar 2026 was $1.3 billion, a 10.25% increase from a year earlier, with the FY2025 full-year figure at $1.2 billion, up 4.29% from the prior year.
• Revenue eased to $317.0 million in Q1 2026 per INDV's latest filing, from $358.0 million in the prior quarter.
• Across five years, Revenue topped out at $358.0 million in Q4 2025 and bottomed at $266.0 million in Q1 2025.
• The 3-year median for Revenue is $302.0 million (2025), against an average of $305.1 million.
• Biggest YoY gain for Revenue was 19.73% in 2025; the steepest drop was 6.34% in 2025.
• Year by year, Revenue stood at $299.0 million in 2024, then gained by 19.73% to $358.0 million in 2025, then retreated by 11.45% to $317.0 million in 2026.
• Per Business Quant, the three latest INDV Revenue figures stand at $317.0 million (Q1 2026), $358.0 million (Q4 2025), and $314.0 million (Q3 2025).